CTO) medical director. Cho will be responsible for overseeing the
UH Cancer Center’s clinical trials administered through
CTO. He has been a faculty member of the
UH Cancer Center since 1991, and has served the people of Hawaiʻi as a local oncologist for more than 29 years. Since 2016, the
UH Cancer Center has enrolled more than 16,000 patients in clinical trials in Hawaiʻi.
Cho is no stranger to clinical trials in Hawaiʻi, having been a strong advocate for clinical trials and enrolling many patients on
UH Cancer Center trials as a leading community oncologist. He led the
UH Cancer Center’s
Operator
Greetings and welcome to TG Therapeutics Q1 2021 Earnings Conference Call and Business Update. [Operator Instructions] I would now like to turn the conference over to Jenna Bosco, Senior VP of Corporate Communications. Please proceed.
Jenna Bosco
Senior Vice President, Corporate Communications
Thank you. Welcome, everyone, and thanks for joining us this morning. I m Jenna Bosco, and with me today to discuss the first quarter 2021 financial results and provide a business update are Michael Weiss, our Executive Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercialization Officer; and Sean Power, our Chief Financial Officer. Following our Safe Harbor statement, Mike will provide an overview of our recent corporate developments as well as an update on our current pivotal programs and key goals for 2021, Adam will provide an update on our commercialization efforts, and Sean will provide a brief overview of our financial results before turning the call o
E-Mail
IMAGE: A preclinical study shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using. view more
Credit: MD Anderson Cancer Center
Abstract #LB008
HOUSTON A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug conjugate (ADC) targeting surface protein MT1-MMP can act as a guided missile in eradicating osteosarcoma tumor cells without damaging normal tissues. This technology, using precision therapy targeting of cell-surface proteins through a Bicycle toxin conjugate (BTC), shows encouraging results for the treatment of osteosarcoma.
Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.